S0000 Selenium and Vitamin E in Preventing Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

35,533

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

May 31, 2011

Study Completion Date

September 30, 2012

Conditions
Prostate Cancer
Interventions
DRUG

Vitamin E

400 IU daily by mouth for 7-12 years

DRUG

Selenium

200 mcg daily for 7-12 years

OTHER

Vitamin E placebo

daily for 7-12 years

OTHER

selenium placebo

daily for 7-12 years

Trial Locations (13)

16801

Geisinger Medical Group - Scenery Park, State College

18711

Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre

44501

Tod Children's Hospital, Youngstown

45220

Good Samaritan Hospital Cancer Treatment Center, Cincinnati

45242

Bethesda North Hospital, Cincinnati

60153

Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood

60432

Midwest Center for Hematology/Oncology, Joliet

65802

CCOP - Cancer Research for the Ozarks, Springfield

65804

St. John's Regional Health Center, Springfield

74104

LaFortune Cancer Center at St. John Medical Center, Tulsa

60611-3013

Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago

17822-0001

Geisinger Medical Center, Danville

37920-6999

U.T. Cancer Institute at University of Tennessee Medical Center, Knoxville

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Eastern Cooperative Oncology Group

NETWORK

collaborator

Cancer and Leukemia Group B

NETWORK

collaborator

NCIC Clinical Trials Group

NETWORK

lead

SWOG Cancer Research Network

NETWORK

NCT00006392 - S0000 Selenium and Vitamin E in Preventing Prostate Cancer | Biotech Hunter | Biotech Hunter